文献速递血栓与止血

可手术慢性血栓栓塞性肺动脉高压抗凝治疗的多中心研究

A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension.
PubMed 文献 · J Thromb Haemost · 2019-10-18

该回顾性多中心研究纳入2007至2018年接受肺动脉内膜剥脱术的慢性血栓栓塞性肺动脉高压患者,比较术后使用维生素K拮抗剂与直接口服抗凝药的安全性和有效性。结果显示两组血流动力学和功能状态均显著改善,大出血事件相当,但直接口服抗凝药组静脉血栓栓塞复发率显著更高。

要点

  • 术后大出血事件在维生素K拮抗剂和直接口服抗凝药组相当。
  • 直接口服抗凝药组静脉血栓栓塞复发率显著高于维生素K拮抗剂组。
  • 抗凝药选择不影响术后血流动力学和功能状态改善。

核心结论

  • 肺动脉内膜剥脱术后功能和血流动力学 outcomes 不受抗凝药选择影响。
  • 直接口服抗凝药组静脉血栓栓塞复发率显著高于维生素K拮抗剂组,尽管生存无差异。

研究设计与样本

  • 回顾性分析纳入2007至2018年连续接受肺动脉内膜剥脱术的慢性血栓栓塞性肺动脉高压患者。
  • 平均观察期612天(标准差702天)。

主要发现

  • 两组术后血流动力学和功能状态均显著改善(P < .001)。
  • 大出血事件在维生素K拮抗剂组(0.67%/人年)和直接口服抗凝药组(0.68%/人年)相当(P = 1)。
  • 静脉血栓栓塞复发率直接口服抗凝药组(4.62%/人年)比例更高(P = .008)于维生素K拮抗剂组(0.76%/人年)。
  • 生存率两组无差异。

临床怎么用

  • 肺动脉内膜剥脱术后使用维生素K拮抗剂可能与更低的静脉血栓栓塞复发率相关。
  • 直接口服抗凝药在慢性血栓栓塞性肺动脉高压中的安全性需前瞻性注册数据进一步评估。

局限性

  • 回顾性分析设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is an uncommon complication of acute pulmonary emboli necessitating lifelong anticoagulation. Despite this, few data exist on the safety and efficacy of vitamin K antagonists (VKAs) in CTEPH and none for direct oral anticoagulants (DOACs). OBJECTIVES: To evaluate outcomes and complication rates in CTEPH following pulmonary endarterectomy (PEA) for individuals receiving VKAs or DOACs. METHODS: Consecutive CTEPH patients undergoing PEA between 2007 and 2018 were included in a retrospective analysis. Postoperative outcomes, recurrent venous thromboembolism (VTE), and bleeding events were obtained from patient medical records. RESULTS: Seven hundred ninety-four individuals were treated with VKAs and 206 with DOACs following PEA. Mean observation period was 612 (standard deviation: 702) days. Significant improvements in hemodynamics and functional status were observed in both groups following PEA (P < .001). Major bleeding events were equivalent (P = 1) in those treated with VKAs (0.67%/person-year) and DOACs (0.68%/person-year). The VTE recurrence was proportionately higher (P = .008) with DOACs (4.62%/person-year) than VKAs (0.76%/person-year), although survival did not differ. CONCLUSIONS: Post-PEA functional and hemodynamic outcomes appear unaffected by anticoagulant choice. Bleeding events were similar, but recurrent VTE rates significantly higher in those receiving DOACs. Our study provides a strong rationale for prospective registry data and/or studies to evaluate the safety of DOACs in CTEPH.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Bunclark K, Newnham M, Chiu YD, et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2019. PMID: 31557382. doi:10.1111/jth.14649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。